Literature DB >> 32663295

Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute.

Robert J Soiffer1.   

Abstract

This article has a companion Point by Scott.
© 2020 by The American Society of Hematology.

Entities:  

Mesh：

Year:  2020        PMID： 32663295      PMCID： PMC7362380          DOI： 10.1182/bloodadvances.2019000389

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  25 in total

1.  Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.

Authors:  Steven Le Gouill; Catherine Thieblemont; Lucie Oberic; Anne Moreau; Krimo Bouabdallah; Caroline Dartigeas; Gandhi Damaj; Thomas Gastinne; Vincent Ribrag; Pierre Feugier; Olivier Casasnovas; Hacène Zerazhi; Corinne Haioun; Hervé Maisonneuve; Roch Houot; Fabrice Jardin; Eric Van Den Neste; Olivier Tournilhac; Katell Le Dû; Franck Morschhauser; Guillaume Cartron; Luc-Matthieu Fornecker; Danielle Canioni; Mary Callanan; Marie C Béné; Gilles Salles; Hervé Tilly; Thierry Lamy; Remy Gressin; Olivier Hermine
Journal:  N Engl J Med       Date:  2017-09-28       Impact factor: 91.245

2.  Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.

Authors:  Gail J Roboz; Courtney D DiNardo; Eytan M Stein; Stéphane de Botton; Alice S Mims; Gabrielle T Prince; Jessica K Altman; Martha L Arellano; Will Donnellan; Harry P Erba; Gabriel N Mannis; Daniel A Pollyea; Anthony S Stein; Geoffrey L Uy; Justin M Watts; Amir T Fathi; Hagop M Kantarjian; Martin S Tallman; Sung Choe; David Dai; Bin Fan; Hongfang Wang; Vickie Zhang; Katharine E Yen; Stephanie M Kapsalis; Denice Hickman; Hua Liu; Samuel V Agresta; Bin Wu; Eyal C Attar; Richard M Stone
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

3.  Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.

Authors:  Yi-Bin Chen; Shuli Li; Andrew A Lane; Christine Connolly; Candice Del Rio; Betsy Valles; Morgan Curtis; Karen Ballen; Corey Cutler; Bimalangshu R Dey; Areej El-Jawahri; Amir T Fathi; Vincent T Ho; Amy Joyce; Steven McAfee; Michelle Rudek; Trivikram Rajkhowa; Sigitas Verselis; Joseph H Antin; Thomas R Spitzer; Mark Levis; Robert Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-17       Impact factor: 5.742

Review 4.  Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Sebastian Giebel; Anna Czyz; Oliver Ottmann; Frederic Baron; Eolia Brissot; Fabio Ciceri; Jan J Cornelissen; Jordi Esteve; Norbert-Claude Gorin; Bipin Savani; Christoph Schmid; Mohamad Mohty; Arnon Nagler
Journal:  Cancer       Date:  2016-06-16       Impact factor: 6.860

5.  Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Authors:  Eolia Brissot; Myriam Labopin; Marielle M Beckers; Gérard Socié; Alessandro Rambaldi; Liisa Volin; Jürgen Finke; Stig Lenhoff; Nicolaus Kröger; Gert J Ossenkoppele; Charles F Craddock; Ibrahim Yakoub-Agha; Günhan Gürman; Nigel H Russell; Mahmoud Aljurf; Michael N Potter; Armon Nagler; Oliver Ottmann; Jan J Cornelissen; Jordi Esteve; Mohamad Mohty
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

6.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

7.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Authors:  Philip L McCarthy; Sarah A Holstein; Maria Teresa Petrucci; Paul G Richardson; Cyrille Hulin; Patrizia Tosi; Sara Bringhen; Pellegrino Musto; Kenneth C Anderson; Denis Caillot; Francesca Gay; Philippe Moreau; Gerald Marit; Sin-Ho Jung; Zhinuan Yu; Benjamin Winograd; Robert D Knight; Antonio Palumbo; Michel Attal
Journal:  J Clin Oncol       Date:  2017-07-25       Impact factor: 44.544

8.  Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Authors:  Giorgia Battipaglia; Annalisa Ruggeri; Radwan Massoud; Jean El Cheikh; Matthieu Jestin; Ahmad Antar; Syed Osman Ahmed; Walid Rasheed; Marwan Shaheen; Ramdane Belhocine; Eolia Brissot; Remy Dulery; Sandra Eder; Federica Giannotti; Francoise Isnard; Simona Lapusan; Marie-Therese Rubio; Anne Vekhoff; Mahmoud Aljurf; Ollivier Legrand; Mohamad Mohty; Ali Bazarbachi
Journal:  Cancer       Date:  2017-04-07       Impact factor: 6.860

9.  Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors:  Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-09       Impact factor: 5.742

10.  CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Authors:  Marcos de Lima; Betul Oran; Richard E Champlin; Esperanza B Papadopoulos; Sergio A Giralt; Bart L Scott; Basem M William; Joel Hetzer; Eric Laille; Becky Hubbell; Barry S Skikne; Charles Craddock
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-20       Impact factor: 5.742
View more
  3 in total

Review 1.  HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?

Authors:  Syaza Ab Rahman; Toni Matic; Maya Yordanova; Hany Ariffin
Journal:  Front Pediatr       Date:  2022-01-21       Impact factor: 3.418

Review 2.  60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

Authors:  Nicoletta Cieri; Katie Maurer; Catherine J Wu
Journal:  Cancer Res       Date:  2021-06-09       Impact factor: 12.701

3.  Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.

Authors:  Siok-Keen Tey; Steven W Lane
Journal:  Blood Adv       Date:  2022-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.